董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Kimberly M. Murphy | 女 | President, Chief Executive Officer and Director | 62 | 52.28万美元 | 未持股 | 2025-09-01 |
| Bruce A. Cassidy | 男 | Director | 75 | 未披露 | 未持股 | 2025-09-01 |
| Susan Mogensen | 女 | Director | 74 | 未披露 | 未持股 | 2025-09-01 |
| Bruce Cassidy | -- | Director | 74 | 未披露 | 未持股 | 2025-09-01 |
| Frederick W. Telling | 男 | Director | 73 | 29.97万美元 | 未持股 | 2025-09-01 |
| Alan W. Dunton | 男 | Director | 71 | 15.28万美元 | 未持股 | 2025-09-01 |
| John P. Gandolfo | 男 | Director | 64 | 未披露 | 未持股 | 2025-09-01 |
| Natasha Giordano | 女 | Director | 65 | 未披露 | 未持股 | 2025-09-01 |
| Charles L. Pope | 男 | Executive Chairman and Director | 73 | 15.95万美元 | 未持股 | 2025-09-01 |
| Robert C. Koski | 男 | Director | 66 | 13.20万美元 | 未持股 | 2025-09-01 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Kimberly M. Murphy | 女 | President, Chief Executive Officer and Director | 62 | 52.28万美元 | 未持股 | 2025-09-01 |
| Janet Huffman | 女 | Chief Financial Officer, Secretary and Treasurer, Interim Chief Executive Officer | 53 | 未披露 | 未持股 | 2025-09-01 |
| Joseph Michael Redmond | -- | Interim Principal Executive Officer, President | 64 | 未披露 | 未持股 | 2025-09-01 |
| Charles L. Pope | 男 | Executive Chairman and Director | 73 | 15.95万美元 | 未持股 | 2025-09-01 |
董事简历
中英对照 | 中文 | 英文- Kimberly M. Murphy
-
Kimberly M.Murphy自2020年5月起担任董事。加入公司之前，Murphy女士曾担任GlaxoSmithKline plc NYSE:GSK（“；GSK”；）流感专营权副总裁和全球疫苗商业化负责人，在那里她领导全球流感疫苗业务，全球疫苗和抗病毒药物的大流行准备，生命周期管理，业务开发和全球P&L管理。Murphy女士目前担任Blue Water AcquisitionCorp.（NASDAQ:BLUW）的董事。Murphy女士还担任Shingrix的带状疱疹疫苗的副总裁兼全球营销主管。从2014年6月到2015年5月，Murphy女士担任北美疫苗整合规划团队的副总裁和领导，负责GSK’；S收购Novartis AG’；S疫苗部门的整合规划。从2012年10月到2014年6月，她担任美国疫苗客户战略的副总裁，从2011年3月到2012年10月，她担任美国流感投资组合战略的高级总监。在2011年3月加入GSK之前，Murphy女士在Novartis Vaccines and Diagnostics Inc.（Novartis AG（NYSE:NVS）的一个部门）工作，担任美国脑膜炎球菌专营权的主管。在Novartis工作之前，Murphy女士在默克制药公司（NYSE:MRK）享有卓越的职业生涯。Murphy女士此前曾担任一家私营疫苗开发公司、生物技术行业组织、生物防御咨询委员会和圣约瑟夫大学制药和医疗保健营销MBA项目的董事会和顾问职务。Murphy女士拥有Old Dominion University的英语学士学位和Saint Joseph’；S University的市场营销硕士学位。墨菲还完成了宾夕法尼亚大学沃顿商学院（Wharton School of Pennsylvania）的卓越营销项目。
Kimberly M. Murphy was appointed President and Chief Executive Officer of the Company on June 23, 2022. She has served as a director since May 2020. Before joining the Company, Ms. Murphy served as Vice President of the Influenza Franchise and Global Vaccine Commercialization Leader at GlaxoSmithKline plc (NYSE: GSK) ("GSK"), where she led the global influenza vaccines business, global pandemic preparedness across vaccines and antivirals, lifecycle management, business development, and global P&L management. Ms. Murphy currently serves as a director of Blue Water Vaccines, Inc. (NASDAQ: BWV) and as a director (chairperson) of Clarus Therapeutics Holdings Inc. (OTC PK: CRXTQ). Ms. Murphy also served as Vice President and Global Marketing Head for the shingles vaccine, SHINGRIX. From June 2014 to May 2015, Ms. Murphy was Vice President and Lead for the North America Vaccines Integration Planning Team, responsible for the integration planning of GSK's acquisition of Novartis AG's vaccine division. From October 2012 to June 2014, Ms. Murphy served as Vice President of U.S. Vaccines Customer Strategy and from March 2011 to October 2012, she served as the Senior Director of U.S. Influenza Portfolio Strategy. Prior to joining GSK in March 2011, Ms. Murphy worked for Novartis Vaccines and Diagnostics Inc., a division of Novartis AG (NYSE: NVS), as the head of the U.S. Meningococcal Franchise. Before working for Novartis, Ms. Murphy enjoyed a distinguished career at Merck & Co., Inc. (NYSE: MRK). Ms. Murphy has previously served in board and advisory roles for a privately-held vaccine development company, the Biotechnology Industry Organization, the Biodefense Advisory Council, and the Saint Joseph's University Pharmaceutical & Healthcare Marketing MBA Program. Ms. Murphy holds a B.A. degree in English from Old Dominion University and a M.B.A. degree in Marketing from Saint Joseph's University. Ms. Murphy has also completed the Marketing Excellence Program at the Wharton School of the University of Pennsylvania. - Kimberly M.Murphy自2020年5月起担任董事。加入公司之前，Murphy女士曾担任GlaxoSmithKline plc NYSE:GSK（“；GSK”；）流感专营权副总裁和全球疫苗商业化负责人，在那里她领导全球流感疫苗业务，全球疫苗和抗病毒药物的大流行准备，生命周期管理，业务开发和全球P&L管理。Murphy女士目前担任Blue Water AcquisitionCorp.（NASDAQ:BLUW）的董事。Murphy女士还担任Shingrix的带状疱疹疫苗的副总裁兼全球营销主管。从2014年6月到2015年5月，Murphy女士担任北美疫苗整合规划团队的副总裁和领导，负责GSK’；S收购Novartis AG’；S疫苗部门的整合规划。从2012年10月到2014年6月，她担任美国疫苗客户战略的副总裁，从2011年3月到2012年10月，她担任美国流感投资组合战略的高级总监。在2011年3月加入GSK之前，Murphy女士在Novartis Vaccines and Diagnostics Inc.（Novartis AG（NYSE:NVS）的一个部门）工作，担任美国脑膜炎球菌专营权的主管。在Novartis工作之前，Murphy女士在默克制药公司（NYSE:MRK）享有卓越的职业生涯。Murphy女士此前曾担任一家私营疫苗开发公司、生物技术行业组织、生物防御咨询委员会和圣约瑟夫大学制药和医疗保健营销MBA项目的董事会和顾问职务。Murphy女士拥有Old Dominion University的英语学士学位和Saint Joseph’；S University的市场营销硕士学位。墨菲还完成了宾夕法尼亚大学沃顿商学院（Wharton School of Pennsylvania）的卓越营销项目。
- Kimberly M. Murphy was appointed President and Chief Executive Officer of the Company on June 23, 2022. She has served as a director since May 2020. Before joining the Company, Ms. Murphy served as Vice President of the Influenza Franchise and Global Vaccine Commercialization Leader at GlaxoSmithKline plc (NYSE: GSK) ("GSK"), where she led the global influenza vaccines business, global pandemic preparedness across vaccines and antivirals, lifecycle management, business development, and global P&L management. Ms. Murphy currently serves as a director of Blue Water Vaccines, Inc. (NASDAQ: BWV) and as a director (chairperson) of Clarus Therapeutics Holdings Inc. (OTC PK: CRXTQ). Ms. Murphy also served as Vice President and Global Marketing Head for the shingles vaccine, SHINGRIX. From June 2014 to May 2015, Ms. Murphy was Vice President and Lead for the North America Vaccines Integration Planning Team, responsible for the integration planning of GSK's acquisition of Novartis AG's vaccine division. From October 2012 to June 2014, Ms. Murphy served as Vice President of U.S. Vaccines Customer Strategy and from March 2011 to October 2012, she served as the Senior Director of U.S. Influenza Portfolio Strategy. Prior to joining GSK in March 2011, Ms. Murphy worked for Novartis Vaccines and Diagnostics Inc., a division of Novartis AG (NYSE: NVS), as the head of the U.S. Meningococcal Franchise. Before working for Novartis, Ms. Murphy enjoyed a distinguished career at Merck & Co., Inc. (NYSE: MRK). Ms. Murphy has previously served in board and advisory roles for a privately-held vaccine development company, the Biotechnology Industry Organization, the Biodefense Advisory Council, and the Saint Joseph's University Pharmaceutical & Healthcare Marketing MBA Program. Ms. Murphy holds a B.A. degree in English from Old Dominion University and a M.B.A. degree in Marketing from Saint Joseph's University. Ms. Murphy has also completed the Marketing Excellence Program at the Wharton School of the University of Pennsylvania.
- Bruce A. Cassidy
-
Bruce A. Cassidy是Loop Media, Inc.董事会成员。自2020年初以来，他一直是Loop Media, Inc.的董事会成员。除了在Loop Media, Inc.的董事会任职外，Cassidy先生目前还在多家公司的董事会任职，包括担任Ultimate Gamer、Assisted 4 Living，Inc.和SegMint的Shlomo Kramer。他担任Sarasota Green Group的主席、Celebyou LLC和Celebyou Productions各自的执行主席，并且是Selinsky Force LLC的董事会成员。他还是Ohio Legacy Corp.的创始投资者和董事会成员。此前，Cassidy先生从1991年到2007年将Excel Mining Systems出售给Orica Mining Services，一直是Excel Mining Systems的创始人兼首席执行官，并于2008年至2009年担任其子公司之一Minora North & South Americas的总裁兼首席执行官。他目前是佛罗里达州萨拉索塔特许高尔夫俱乐部的主席。
Bruce A. Cassidy,has been a member of Loop Media, Inc. Board of Directors since December 2019 and has served as Chairman of the Board since November 2022. In addition to his role on Loop Media, Inc. Board of Directors, Mr. Cassidy currently serves on the boards for various companies, including as chairman of the board of each of Assisted 4 Living, Inc., KeyStar Corporation (d/b/a Zensports) and the Sarasota Green Group, and as a member of the board of Oragenics, Inc. He was also the founding investor and served on the board of directors of Ohio Legacy Corp. Previously, Mr. Cassidy was the founder and CEO of Excel Mining Systems from 1991 until its sale in 2007 to Orica Mining Services, and from 2008 to 2009, he served as the President and CEO of one of its subsidiaries, Minora North & South Americas. He is currently the President of The Concession Golf Club in Sarasota, Florida. - Bruce A. Cassidy是Loop Media, Inc.董事会成员。自2020年初以来，他一直是Loop Media, Inc.的董事会成员。除了在Loop Media, Inc.的董事会任职外，Cassidy先生目前还在多家公司的董事会任职，包括担任Ultimate Gamer、Assisted 4 Living，Inc.和SegMint的Shlomo Kramer。他担任Sarasota Green Group的主席、Celebyou LLC和Celebyou Productions各自的执行主席，并且是Selinsky Force LLC的董事会成员。他还是Ohio Legacy Corp.的创始投资者和董事会成员。此前，Cassidy先生从1991年到2007年将Excel Mining Systems出售给Orica Mining Services，一直是Excel Mining Systems的创始人兼首席执行官，并于2008年至2009年担任其子公司之一Minora North & South Americas的总裁兼首席执行官。他目前是佛罗里达州萨拉索塔特许高尔夫俱乐部的主席。
- Bruce A. Cassidy,has been a member of Loop Media, Inc. Board of Directors since December 2019 and has served as Chairman of the Board since November 2022. In addition to his role on Loop Media, Inc. Board of Directors, Mr. Cassidy currently serves on the boards for various companies, including as chairman of the board of each of Assisted 4 Living, Inc., KeyStar Corporation (d/b/a Zensports) and the Sarasota Green Group, and as a member of the board of Oragenics, Inc. He was also the founding investor and served on the board of directors of Ohio Legacy Corp. Previously, Mr. Cassidy was the founder and CEO of Excel Mining Systems from 1991 until its sale in 2007 to Orica Mining Services, and from 2008 to 2009, he served as the President and CEO of one of its subsidiaries, Minora North & South Americas. He is currently the President of The Concession Golf Club in Sarasota, Florida.
- Susan Mogensen
-
Susan Mogensen，她是Lime的首席法律官，自2024年8月起担任该职位。她拥有超过25年的执行管理层和董事会董事咨询经验，涉及广泛的主题，包括战略、诉讼、合规、监管事务、公司治理、ESG、高管薪酬、财务报告、危机管理、网络安全、人力资本管理、投资者关系、并购、证券、股东参与和财务事务。此前，她在英特尔工作了大约11年，最近担任总法律顾问（临时）。在Intel，她还担任Intel Capital的副总裁兼董事总经理，在那里她为Intel Capital （Intel的全球投资组织，进行股权投资和处理收购、剥离和其他战略交易）的总裁提供主要法律支持。她于2011年加入英特尔投资，担任并购顾问。在加入英特尔之前，她曾在并购法律咨询公司Deal Fusion担任总裁兼首席执行官三年，并在Sun Microsystems任职五年，包括担任并购和战略投资总监。在她的职业生涯早期，她是律师事务所Gunderson Dettmer和Brobeck Phleger & Harrison的律师。她还曾担任Aeris IoT SaaS的总法律顾问。她拥有旧金山大学法学院法学博士学位和加州州立理工大学圣路易斯奥比斯波分校政治学文学学士学位。
Susan Mogensen,has been a member of Board since August 2024. Ms. Giordano is the Chief Legal Officer of Lime, which position she has held since August 2024. Ms. Giordano has over 25 years of experience advising executive management and board directors on a wide range of topics, including strategy, litigation, compliance, regulatory matters, corporate governance, ESG, executive compensation, financial reporting, crisis management, cybersecurity, human capital management, investor relations, M&A, securities, shareholder engagement, and treasury matters. Previously, she worked at Intel for approximately 11 years where she served most recently as general counsel (interim). At Intel, Ms. Giordano also held roles as corporate secretary and vice president and managing director of Intel Capital where she provided primary legal support to the president of Intel Capital, Intel's global investment organization that makes equity investments and handles acquisitions, divestitures and other strategic transactions. She had joined Intel Capital in 2011 as M&A counsel. Before joining Intel, Ms. Giordano spent three years as president and CEO at Deal Fusion, an M&A legal consulting firm, and five years at Sun Microsystems including as director of M&A and strategic investments. Earlier in her career she was an attorney with law firms Gunderson Dettmer and Brobeck Phleger & Harrison. Ms. Giordano also previously served as general counsel at Aeris IoT SaaS. She has a juris doctorate from the University of San Francisco, School of Law and a Bachelor of Arts in political science from California Polytechnic State University, San Luis Obispo. - Susan Mogensen，她是Lime的首席法律官，自2024年8月起担任该职位。她拥有超过25年的执行管理层和董事会董事咨询经验，涉及广泛的主题，包括战略、诉讼、合规、监管事务、公司治理、ESG、高管薪酬、财务报告、危机管理、网络安全、人力资本管理、投资者关系、并购、证券、股东参与和财务事务。此前，她在英特尔工作了大约11年，最近担任总法律顾问（临时）。在Intel，她还担任Intel Capital的副总裁兼董事总经理，在那里她为Intel Capital （Intel的全球投资组织，进行股权投资和处理收购、剥离和其他战略交易）的总裁提供主要法律支持。她于2011年加入英特尔投资，担任并购顾问。在加入英特尔之前，她曾在并购法律咨询公司Deal Fusion担任总裁兼首席执行官三年，并在Sun Microsystems任职五年，包括担任并购和战略投资总监。在她的职业生涯早期，她是律师事务所Gunderson Dettmer和Brobeck Phleger & Harrison的律师。她还曾担任Aeris IoT SaaS的总法律顾问。她拥有旧金山大学法学院法学博士学位和加州州立理工大学圣路易斯奥比斯波分校政治学文学学士学位。
- Susan Mogensen,has been a member of Board since August 2024. Ms. Giordano is the Chief Legal Officer of Lime, which position she has held since August 2024. Ms. Giordano has over 25 years of experience advising executive management and board directors on a wide range of topics, including strategy, litigation, compliance, regulatory matters, corporate governance, ESG, executive compensation, financial reporting, crisis management, cybersecurity, human capital management, investor relations, M&A, securities, shareholder engagement, and treasury matters. Previously, she worked at Intel for approximately 11 years where she served most recently as general counsel (interim). At Intel, Ms. Giordano also held roles as corporate secretary and vice president and managing director of Intel Capital where she provided primary legal support to the president of Intel Capital, Intel's global investment organization that makes equity investments and handles acquisitions, divestitures and other strategic transactions. She had joined Intel Capital in 2011 as M&A counsel. Before joining Intel, Ms. Giordano spent three years as president and CEO at Deal Fusion, an M&A legal consulting firm, and five years at Sun Microsystems including as director of M&A and strategic investments. Earlier in her career she was an attorney with law firms Gunderson Dettmer and Brobeck Phleger & Harrison. Ms. Giordano also previously served as general counsel at Aeris IoT SaaS. She has a juris doctorate from the University of San Francisco, School of Law and a Bachelor of Arts in political science from California Polytechnic State University, San Luis Obispo.
- Bruce Cassidy
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Frederick W. Telling
-
Frederick W. Telling，于2011年2月4日被选举为董事会主席，并在公司前总裁兼首席执行官Joslyn博士辞职后于2021年5月2日被任命为执行主席。Telling博士自2010年6月起担任董事。在服务了30年之后，Telling博士于2007年6月从Pfizer Inc.退休。在Pfizer Inc.，Telling博士担任公司副总裁兼公司战略规划和政策副总裁。Telling博士还在各种公民和非营利组织的董事会任职。Telling博士拥有汉密尔顿学院的历史和经济学学士学位以及康奈尔大学的工业和劳动关系硕士学位和经济学和公共政策博士学位。
Frederick W. Telling,has served as a Director since June 2010. Dr. Telling served as Chairman of the Board of Directors from February 4, 2011, through December 16, 2022 and as Executive Chairman from May 2, 2021 through December 16, 2022. Dr. Telling retired from Pfizer Inc. in June 2007 after 30 years of service. At Pfizer Dr. Telling served as its Corporate Vice President and Vice President of Corporate Strategic Planning and Policy. Dr. Telling also serves on the boards of various civic and non-profit organizations. Dr. Telling holds a B.A. degree in History and Economics from Hamilton College and a MA degree in Industrial and Labor Relations and a PhD in Economics and Public Policy from Cornell University. - Frederick W. Telling，于2011年2月4日被选举为董事会主席，并在公司前总裁兼首席执行官Joslyn博士辞职后于2021年5月2日被任命为执行主席。Telling博士自2010年6月起担任董事。在服务了30年之后，Telling博士于2007年6月从Pfizer Inc.退休。在Pfizer Inc.，Telling博士担任公司副总裁兼公司战略规划和政策副总裁。Telling博士还在各种公民和非营利组织的董事会任职。Telling博士拥有汉密尔顿学院的历史和经济学学士学位以及康奈尔大学的工业和劳动关系硕士学位和经济学和公共政策博士学位。
- Frederick W. Telling,has served as a Director since June 2010. Dr. Telling served as Chairman of the Board of Directors from February 4, 2011, through December 16, 2022 and as Executive Chairman from May 2, 2021 through December 16, 2022. Dr. Telling retired from Pfizer Inc. in June 2007 after 30 years of service. At Pfizer Dr. Telling served as its Corporate Vice President and Vice President of Corporate Strategic Planning and Policy. Dr. Telling also serves on the boards of various civic and non-profit organizations. Dr. Telling holds a B.A. degree in History and Economics from Hamilton College and a MA degree in Industrial and Labor Relations and a PhD in Economics and Public Policy from Cornell University.
- Alan W. Dunton
-
Alan W. Dunton，自2019年3月起担任CorMedix的董事。他是Danerius，LLC的创始人和首席顾问，该公司是他于2006年开始的生物技术和制药咨询业务。从1994年起，他在强生制药部门担任研发高级职务，包括在强生制药部门的主要研究、开发和监管部门杨森公司担任总裁兼董事总经理。从2007年1月到2009年3月，Dunton博士担任Panacos Pharmaceuticals，Inc.的总裁兼首席执行官。从2015年11月到2018年3月，Dunton博士担任私营制药公司Purdue Pharma L.P.的研究、开发和监管事务主管/高级副总裁。除了CorMedix，Dunton博士目前还在三家上市公司的董事会任职。作为PALATIN技术和Oragenics公司的董事，他主持了两家公司的薪酬委员会。他还担任这些公司的审计委员会成员。此外，Dunton博士还是Recce Pharma Ltd.的董事会成员，该公司是一家澳大利亚公共生物技术公司，专注于为严重和危及生命的疾病开发新型抗感染药物。Dunton博士以优异成绩获得纽约州立大学布法罗分校的生物化学理学学士学位，并获得纽约大学医学院的医学博士学位。
Alan W. Dunton,has served as a Director of Oragenics, Inc. since April 2011. He is the principal owner of Danerius, LLC, a biotechnology consulting company which he founded in 2006. In addition to Oragenics, he is currently a Director of the public biotechnology company, Palatin, Inc. (AMEX: PTN), CorMedix (NASDAQ: CRMD) and Recce Pharmaceuticals (ASX: RCE). Dr. Dunton has held significant senior positions in major pharmaceutical companies. Most recent was from November 2015 through March 2018 as the Senior Vice President of Research, Development and Regulatory Affairs of Purdue Pharma L.P., a private pharmaceutical company. From January 2007 until March 2009, Dr. Dunton served as President and Chief Executive Officer of Panacos Pharmaceuticals, Inc. In 2005, Dr. Dunton served as the Non-Executive Chairman of the Board of Directors of ActivBiotics, Inc., a private biopharmaceutical company. Previously, he was the President and Chief Executive Officer of Metaphore Pharmaceuticals, Inc. from 2003 until 2006, when it merged with ActivBiotics. From 2004 until 2005, Dr. Dunton served as a member of the Board of Directors of Vicuron Pharmaceuticals until it was acquired by Pfizer, Inc. In 2002, Dr. Dunton served as President, Chief Operating Officer and a Director of Emisphere Technologies, Inc., a biopharmaceutical company. From 1994 to 2001, Dr. Dunton was a senior executive in various capacities in the Pharmaceuticals Group of Johnson & Johnson. From 1999 to 2001, Dr. Dunton was President and Managing Director of The Janssen Research Foundation, a Johnson & Johnson company. From 1998 to 1999, he served as Group Vice President of Global Clinical Research and Development of Janssen. Prior to joining Janssen, Dr. Dunton was Vice President of Global Clinical Research and Development at the R.W. Johnson Pharmaceutical Research Institute, also a Johnson & Johnson company. Prior to joining Johnson & Johnson, Dr. Dunton held positions in clinical research and development at Syntex Corporation, CIBA-GEIGY Corporation and Hoffmann La Roche Inc. Dr. Dunton holds a MD degree from New York University School of Medicine, where he completed his residency in internal medicine. He also was a Fellow in Clinical Pharmacology at the New York Hospital/Cornell University Medical Center. - Alan W. Dunton，自2019年3月起担任CorMedix的董事。他是Danerius，LLC的创始人和首席顾问，该公司是他于2006年开始的生物技术和制药咨询业务。从1994年起，他在强生制药部门担任研发高级职务，包括在强生制药部门的主要研究、开发和监管部门杨森公司担任总裁兼董事总经理。从2007年1月到2009年3月，Dunton博士担任Panacos Pharmaceuticals，Inc.的总裁兼首席执行官。从2015年11月到2018年3月，Dunton博士担任私营制药公司Purdue Pharma L.P.的研究、开发和监管事务主管/高级副总裁。除了CorMedix，Dunton博士目前还在三家上市公司的董事会任职。作为PALATIN技术和Oragenics公司的董事，他主持了两家公司的薪酬委员会。他还担任这些公司的审计委员会成员。此外，Dunton博士还是Recce Pharma Ltd.的董事会成员，该公司是一家澳大利亚公共生物技术公司，专注于为严重和危及生命的疾病开发新型抗感染药物。Dunton博士以优异成绩获得纽约州立大学布法罗分校的生物化学理学学士学位，并获得纽约大学医学院的医学博士学位。
- Alan W. Dunton,has served as a Director of Oragenics, Inc. since April 2011. He is the principal owner of Danerius, LLC, a biotechnology consulting company which he founded in 2006. In addition to Oragenics, he is currently a Director of the public biotechnology company, Palatin, Inc. (AMEX: PTN), CorMedix (NASDAQ: CRMD) and Recce Pharmaceuticals (ASX: RCE). Dr. Dunton has held significant senior positions in major pharmaceutical companies. Most recent was from November 2015 through March 2018 as the Senior Vice President of Research, Development and Regulatory Affairs of Purdue Pharma L.P., a private pharmaceutical company. From January 2007 until March 2009, Dr. Dunton served as President and Chief Executive Officer of Panacos Pharmaceuticals, Inc. In 2005, Dr. Dunton served as the Non-Executive Chairman of the Board of Directors of ActivBiotics, Inc., a private biopharmaceutical company. Previously, he was the President and Chief Executive Officer of Metaphore Pharmaceuticals, Inc. from 2003 until 2006, when it merged with ActivBiotics. From 2004 until 2005, Dr. Dunton served as a member of the Board of Directors of Vicuron Pharmaceuticals until it was acquired by Pfizer, Inc. In 2002, Dr. Dunton served as President, Chief Operating Officer and a Director of Emisphere Technologies, Inc., a biopharmaceutical company. From 1994 to 2001, Dr. Dunton was a senior executive in various capacities in the Pharmaceuticals Group of Johnson & Johnson. From 1999 to 2001, Dr. Dunton was President and Managing Director of The Janssen Research Foundation, a Johnson & Johnson company. From 1998 to 1999, he served as Group Vice President of Global Clinical Research and Development of Janssen. Prior to joining Janssen, Dr. Dunton was Vice President of Global Clinical Research and Development at the R.W. Johnson Pharmaceutical Research Institute, also a Johnson & Johnson company. Prior to joining Johnson & Johnson, Dr. Dunton held positions in clinical research and development at Syntex Corporation, CIBA-GEIGY Corporation and Hoffmann La Roche Inc. Dr. Dunton holds a MD degree from New York University School of Medicine, where he completed his residency in internal medicine. He also was a Fellow in Clinical Pharmacology at the New York Hospital/Cornell University Medical Center.
- John P. Gandolfo
-
John P. Gandolfo，自2013年10月起担任董事。他拥有大约33年的经验，担任多家快速增长的私人和上市公司的首席财务官（“CFO”），主要关注生命科学、医疗保健和医疗设备领域。在他的职业生涯中，他直接负责融资，包括五次公开发行、财务管理、并购交易和SEC报告。从2018年1月至今，他担任Eyenovia， Inc. （EYEN）的首席财务官，EYEN是一家后期眼科生物制药公司。在此之前，他从2010年7月到2017年9月担任生物制剂公司Xtant Medical Holdings， Inc.的首席财务官。在此之前，从2009年1月到2010年6月，他担任Progenitor Cell Therapy LLC的首席财务官。在此之前，从2007年1月到2009年1月，他担任Power Medical Interventions， Inc.的首席财务官。在此之前，他是Bioject Medical Technologies， Inc.的首席财务官。2000年至2001年9月，他担任Capital Access Network， Inc.的首席财务官；1999年至2000年，他担任Xceed， Inc.的首席财务官。从1994年到1999年，他担任Impath， Inc.的首席财务官和首席运营官。从1987年到1994年，他担任Medical Resources， Inc.的首席财务官。Gandolfo先生此前于2019年至2023年担任Odyssey Health， Inc.（奥德赛集团国际公司）的董事会成员，并担任审计委员会主席。Gandolfo先生目前是Electrocore， Inc. （ECOR）的董事会成员，薪酬委员会主席和审计委员会成员。他持有Rutgers大学的工商管理学士学位。
John P. Gandolfo,has served as Director since October, 2023. Mr. Gandolfo has approximately 33 years of experience as a Chief Financial Officer ("CFO") of multiple rapidly growing private and publicly held companies with a primary focus in the life sciences, healthcare and medical device areas. Mr. Gandolfo has had direct responsibility over capital raising, including five public offerings, financial management, mergers and acquisition transactions and SEC reporting throughout his professional career. Mr. Gandolfo served as CFO of Eyenovia, Inc., (EYEN) a late-stage ophthalmic biopharmaceutical company, from January 2018 to present. Prior to this, Mr. Gandolfo was CFO of Xtant Medical Holdings, Inc., a biologics company, from July 2010 through September 2017. Prior to this, he served as the CFO for Progenitor Cell Therapy LLC from January 2009 to June 2010 and, before that, as CFO of Power Medical Interventions, Inc. from January 2007 to January 2009. Mr. Gandolfo was the CFO of Bioject Medical Technologies, Inc. prior to this. He was also the CFO of Capital Access Network, Inc., from 2000 through September 2001, and Xceed, Inc. from 1999 to 2000. From 1994 to 1999, Mr. Gandolfo was CFO and COO of Impath, Inc. From 1987 through 1994, he was CFO of Medical Resources, Inc. Mr. Gandolfo previously served on the Board of Directors and was chair of the Audit Committee of Odyssey Health, Inc. f/k/a Odyssey Group International, Inc., (ODDY) from 2019 until 2023. Mr. Gandolfo is currently a member of the Board of Directors of Electrocore, Inc. (ECOR) and is chair of the Compensation Committee and sits on their audit committee. Mr. Gandolfo received his B.A. degree in Business Administration from Rutgers University. - John P. Gandolfo，自2013年10月起担任董事。他拥有大约33年的经验，担任多家快速增长的私人和上市公司的首席财务官（“CFO”），主要关注生命科学、医疗保健和医疗设备领域。在他的职业生涯中，他直接负责融资，包括五次公开发行、财务管理、并购交易和SEC报告。从2018年1月至今，他担任Eyenovia， Inc. （EYEN）的首席财务官，EYEN是一家后期眼科生物制药公司。在此之前，他从2010年7月到2017年9月担任生物制剂公司Xtant Medical Holdings， Inc.的首席财务官。在此之前，从2009年1月到2010年6月，他担任Progenitor Cell Therapy LLC的首席财务官。在此之前，从2007年1月到2009年1月，他担任Power Medical Interventions， Inc.的首席财务官。在此之前，他是Bioject Medical Technologies， Inc.的首席财务官。2000年至2001年9月，他担任Capital Access Network， Inc.的首席财务官；1999年至2000年，他担任Xceed， Inc.的首席财务官。从1994年到1999年，他担任Impath， Inc.的首席财务官和首席运营官。从1987年到1994年，他担任Medical Resources， Inc.的首席财务官。Gandolfo先生此前于2019年至2023年担任Odyssey Health， Inc.（奥德赛集团国际公司）的董事会成员，并担任审计委员会主席。Gandolfo先生目前是Electrocore， Inc. （ECOR）的董事会成员，薪酬委员会主席和审计委员会成员。他持有Rutgers大学的工商管理学士学位。
- John P. Gandolfo,has served as Director since October, 2023. Mr. Gandolfo has approximately 33 years of experience as a Chief Financial Officer ("CFO") of multiple rapidly growing private and publicly held companies with a primary focus in the life sciences, healthcare and medical device areas. Mr. Gandolfo has had direct responsibility over capital raising, including five public offerings, financial management, mergers and acquisition transactions and SEC reporting throughout his professional career. Mr. Gandolfo served as CFO of Eyenovia, Inc., (EYEN) a late-stage ophthalmic biopharmaceutical company, from January 2018 to present. Prior to this, Mr. Gandolfo was CFO of Xtant Medical Holdings, Inc., a biologics company, from July 2010 through September 2017. Prior to this, he served as the CFO for Progenitor Cell Therapy LLC from January 2009 to June 2010 and, before that, as CFO of Power Medical Interventions, Inc. from January 2007 to January 2009. Mr. Gandolfo was the CFO of Bioject Medical Technologies, Inc. prior to this. He was also the CFO of Capital Access Network, Inc., from 2000 through September 2001, and Xceed, Inc. from 1999 to 2000. From 1994 to 1999, Mr. Gandolfo was CFO and COO of Impath, Inc. From 1987 through 1994, he was CFO of Medical Resources, Inc. Mr. Gandolfo previously served on the Board of Directors and was chair of the Audit Committee of Odyssey Health, Inc. f/k/a Odyssey Group International, Inc., (ODDY) from 2019 until 2023. Mr. Gandolfo is currently a member of the Board of Directors of Electrocore, Inc. (ECOR) and is chair of the Compensation Committee and sits on their audit committee. Mr. Gandolfo received his B.A. degree in Business Administration from Rutgers University.
- Natasha Giordano
-
Natasha Giordano，自2025年7月2日起担任Incora Health的董事会主席，自AugOragenics， Inc.于2024年起担任Afaxys Inc.的薪酬委员会和董事会成员。她目前还担任aqutual， Inc.和Omeza的战略顾问。从2020年9月到2025年2月，她担任Matinas BioPharma（纽约证券交易所代码：MTNB）的董事会成员。2016年1月至2023年7月，她担任PLx Pharma Inc.（纳斯达克股票代码：PLXP）的总裁兼首席执行官，这是一家后期专业制药公司，并担任PLx的董事会成员。从2015年5月到2015年11月，她担任ClearPoint Learning， Inc.（一家私人持有的学习和培训平台公司）的首席执行官。从2009年12月到2015年11月，她还担任ClearPoint董事会成员。从2014年1月到2014年1月，她担任美国医疗保健公司（纽约证券交易所代码：HCA）的首席执行官，这是一家领先的医疗保健提供商。从2009年6月到2012年，她担任Xanodyne Pharmaceuticals， Inc.的首席运营官、首席执行官、总裁和董事会成员，Xanodyne Pharmaceuticals, Inc.是一家私人持有的品牌专业制药公司，具有oragenics， Inc.在疼痛管理和女性健康方面的开发和商业能力。在此之前，她从2007年到2008年担任gegedim Dendrite（前身为Dendrite International Inc.）的美洲总裁，这是一家全球技术服务公司。从2004年到2007年，她担任gegedim Dendrite的global COragenics， Inc.（原gegedim Dendrite的BOragenics， Inc.）的高级副总裁。
Natasha Giordano, since July 2, 2025, has served as the Board Chair for Incora Health and, since AugOragenics, Inc.t 2024, has served on the Compensation Committee and on the Board of Directors of Afaxys Inc. She also is presently serving as a strategic advisor to Aqtual, Inc. and Omeza. PrevioOragenics, Inc.ly, Ms. Giordano served on the Board of Matinas BioPharma (NYSE:MTNB) from September 2020 through February 2025. Ms. Giordano served as President and Chief Executive Officer of PLx Pharma Inc. (NASDAQ: PLXP), a late-stage specialty pharmaceutical company, from January 2016 through July 2023, and served as a member of the board of PLx. PrevioOragenics, Inc.ly, Ms. Giordano served as Chief Executive Officer of ClearPoint Learning, Inc., a privately held learning and training platform company, from May 2015 through November 2015. She also served on the ClearPoint board of directors from December 2009 through November 2015. PrevioOragenics, Inc.ly, Ms. Giordano served as the Chief Executive Officer of Healthcare Corporation of America (NYSE: HCA), a leading healthcare provider, from January 2014 through AugOragenics, Inc.t 2014. From June 2009 to AugOragenics, Inc.t 2012, Ms. Giordano served as Chief Operating Officer and then as Chief Executive Officer, President and a member of the board of directors of Xanodyne Pharmaceuticals, Inc., a privately-held branded specialty pharmaceutical company with development and commercial capabilities focOragenics, Inc.ed on pain management and women's health. Prior to that, she served as President, Americas, for Cegedim Dendrite (formerly Dendrite International Inc.), a global technology services company, from 2007 to 2008 and as Senior Vice President of the Global COragenics, Inc.tomer BOragenics, Inc.iness Unit of Cegedim Dendrite from 2004 to 2007. - Natasha Giordano，自2025年7月2日起担任Incora Health的董事会主席，自AugOragenics， Inc.于2024年起担任Afaxys Inc.的薪酬委员会和董事会成员。她目前还担任aqutual， Inc.和Omeza的战略顾问。从2020年9月到2025年2月，她担任Matinas BioPharma（纽约证券交易所代码：MTNB）的董事会成员。2016年1月至2023年7月，她担任PLx Pharma Inc.（纳斯达克股票代码：PLXP）的总裁兼首席执行官，这是一家后期专业制药公司，并担任PLx的董事会成员。从2015年5月到2015年11月，她担任ClearPoint Learning， Inc.（一家私人持有的学习和培训平台公司）的首席执行官。从2009年12月到2015年11月，她还担任ClearPoint董事会成员。从2014年1月到2014年1月，她担任美国医疗保健公司（纽约证券交易所代码：HCA）的首席执行官，这是一家领先的医疗保健提供商。从2009年6月到2012年，她担任Xanodyne Pharmaceuticals， Inc.的首席运营官、首席执行官、总裁和董事会成员，Xanodyne Pharmaceuticals, Inc.是一家私人持有的品牌专业制药公司，具有oragenics， Inc.在疼痛管理和女性健康方面的开发和商业能力。在此之前，她从2007年到2008年担任gegedim Dendrite（前身为Dendrite International Inc.）的美洲总裁，这是一家全球技术服务公司。从2004年到2007年，她担任gegedim Dendrite的global COragenics， Inc.（原gegedim Dendrite的BOragenics， Inc.）的高级副总裁。
- Natasha Giordano, since July 2, 2025, has served as the Board Chair for Incora Health and, since AugOragenics, Inc.t 2024, has served on the Compensation Committee and on the Board of Directors of Afaxys Inc. She also is presently serving as a strategic advisor to Aqtual, Inc. and Omeza. PrevioOragenics, Inc.ly, Ms. Giordano served on the Board of Matinas BioPharma (NYSE:MTNB) from September 2020 through February 2025. Ms. Giordano served as President and Chief Executive Officer of PLx Pharma Inc. (NASDAQ: PLXP), a late-stage specialty pharmaceutical company, from January 2016 through July 2023, and served as a member of the board of PLx. PrevioOragenics, Inc.ly, Ms. Giordano served as Chief Executive Officer of ClearPoint Learning, Inc., a privately held learning and training platform company, from May 2015 through November 2015. She also served on the ClearPoint board of directors from December 2009 through November 2015. PrevioOragenics, Inc.ly, Ms. Giordano served as the Chief Executive Officer of Healthcare Corporation of America (NYSE: HCA), a leading healthcare provider, from January 2014 through AugOragenics, Inc.t 2014. From June 2009 to AugOragenics, Inc.t 2012, Ms. Giordano served as Chief Operating Officer and then as Chief Executive Officer, President and a member of the board of directors of Xanodyne Pharmaceuticals, Inc., a privately-held branded specialty pharmaceutical company with development and commercial capabilities focOragenics, Inc.ed on pain management and women's health. Prior to that, she served as President, Americas, for Cegedim Dendrite (formerly Dendrite International Inc.), a global technology services company, from 2007 to 2008 and as Senior Vice President of the Global COragenics, Inc.tomer BOragenics, Inc.iness Unit of Cegedim Dendrite from 2004 to 2007.
- Charles L. Pope
-
Charles L. Pope，自2008年9月以来一直是本董事会的成员。他曾在2009年6月以来一直在Florida州Tampa市的一个社区银行- The Palm Bank的首席运营官及财务总监。在2007-2009年期间，他曾在一家飞机仪器和显示器的制造商- Aerosonic公司的财务总监及顾问。在2005年2月-2007年4月期间，他曾在一个电子服务和工程服务的生产商- Reptron Manufacturing的财务总监。在2002年4月-2005年2月期间，他曾是一家为医院手术过程中可重复使用和一次性产品的供应商- SRI/Surgical的一位财务总监。此前，他曾在一个收购和投资高校新技术开发的商业开发公司- UTEK公司的财务总监。在2010年2月以来，他一直是Innovaro股份有限公司（OTCQB： INNI）的董事会成员，以及是审计委员会的主席。自2010年6月以来，他一直是Oragenics股份有限公司 （OTCBB： OGEN）的董事会成员，以及是其审计委员会的主席。他曾经在PricewaterhouseCoopers律师事务所工作，最后作为合伙人的身份离开。他拥有Auburn大学的经济和会计学士学位，以及是Florida州的一名注册会计师。
Charles L. Pope,was elected Chairman on December 16, 2022, and has served as a Director since June 2010. Mr. Pope served as the Chief Financial Officer of Palm Bancorp, Inc. from June 2009 to June 2012. From September 2007 through June 2009, Mr. Pope served as the Chief Financial Officer of Aerosonic Inc., a manufacturer of aviation products. Mr. Pope served as the Chief Financial Officer of Reptron Inc., a manufacturer of electronic products, from March 2005 through June 2007. From March 2002 to March 2005, Mr. Pope served as Chief Financial Officer of SRI/Surgical Express, Inc. From February 2001 to March 2002, Mr. Pope served as Chief Financial Officer of Innovaro, Inc. (formerly UTEK Corporation NYSE American: INV) a public company. Mr. Pope served as a Director for Trxade Health, Inc. (NASDAQ: MEDS). Mr. Pope served as a Director of Innovaro, Inc. from March 2010 to August 2012. Mr. Pope also served as a director of Inuvo, Inc. from July 2008 through July 2018. Prior to this time, Mr. Pope served as a Partner in the Audit and Financial Advisory Consulting Divisions of PricewaterhouseCoopers LLP, and he was also a Partner in the Accounting and SEC Directorate in PricewaterhouseCoopers LLP's New York City office. Mr. Pope holds a B.S. degree in Economics and Accounting from Auburn University and is a Certified Public Accountant in Florida. - Charles L. Pope，自2008年9月以来一直是本董事会的成员。他曾在2009年6月以来一直在Florida州Tampa市的一个社区银行- The Palm Bank的首席运营官及财务总监。在2007-2009年期间，他曾在一家飞机仪器和显示器的制造商- Aerosonic公司的财务总监及顾问。在2005年2月-2007年4月期间，他曾在一个电子服务和工程服务的生产商- Reptron Manufacturing的财务总监。在2002年4月-2005年2月期间，他曾是一家为医院手术过程中可重复使用和一次性产品的供应商- SRI/Surgical的一位财务总监。此前，他曾在一个收购和投资高校新技术开发的商业开发公司- UTEK公司的财务总监。在2010年2月以来，他一直是Innovaro股份有限公司（OTCQB： INNI）的董事会成员，以及是审计委员会的主席。自2010年6月以来，他一直是Oragenics股份有限公司 （OTCBB： OGEN）的董事会成员，以及是其审计委员会的主席。他曾经在PricewaterhouseCoopers律师事务所工作，最后作为合伙人的身份离开。他拥有Auburn大学的经济和会计学士学位，以及是Florida州的一名注册会计师。
- Charles L. Pope,was elected Chairman on December 16, 2022, and has served as a Director since June 2010. Mr. Pope served as the Chief Financial Officer of Palm Bancorp, Inc. from June 2009 to June 2012. From September 2007 through June 2009, Mr. Pope served as the Chief Financial Officer of Aerosonic Inc., a manufacturer of aviation products. Mr. Pope served as the Chief Financial Officer of Reptron Inc., a manufacturer of electronic products, from March 2005 through June 2007. From March 2002 to March 2005, Mr. Pope served as Chief Financial Officer of SRI/Surgical Express, Inc. From February 2001 to March 2002, Mr. Pope served as Chief Financial Officer of Innovaro, Inc. (formerly UTEK Corporation NYSE American: INV) a public company. Mr. Pope served as a Director for Trxade Health, Inc. (NASDAQ: MEDS). Mr. Pope served as a Director of Innovaro, Inc. from March 2010 to August 2012. Mr. Pope also served as a director of Inuvo, Inc. from July 2008 through July 2018. Prior to this time, Mr. Pope served as a Partner in the Audit and Financial Advisory Consulting Divisions of PricewaterhouseCoopers LLP, and he was also a Partner in the Accounting and SEC Directorate in PricewaterhouseCoopers LLP's New York City office. Mr. Pope holds a B.S. degree in Economics and Accounting from Auburn University and is a Certified Public Accountant in Florida.
- Robert C. Koski
-
Robert C. Koski自2009年6月起担任董事。Koski先生自1992年以来一直在Koski公司担任律师，该公司是一家位于佐治亚州亚特兰大的独资公司，他的业务包括诉讼和税法。Koski先生还担任Koski家族有限合伙公司的合伙人，该公司实益拥有该公司的权益，并自1996年12月起担任Koski家族基金会的董事。Koski先生拥有科尔盖特大学哲学和英语学士学位、埃默里法学院JD学位以及埃默里大学税务和诉讼法学硕士学位。
Robert C. Koski,has served as a Director since June 2009. Mr. Koski has practiced as an attorney with the Koski Firm, a sole proprietorship located in Atlanta, Georgia since 1992, where his practice includes litigation and tax law. Mr. Koski has also served as a partner in the Koski Family Limited Partnership, which beneficially owns an interest in the Company, and as a Director of the Koski Family Foundation since December 1996. Mr. Koski holds a B.A. degree in Philosophy and English from Colgate University, a JD from Emory School of Law and an LLM degree in Taxation and Litigation from Emory University. - Robert C. Koski自2009年6月起担任董事。Koski先生自1992年以来一直在Koski公司担任律师，该公司是一家位于佐治亚州亚特兰大的独资公司，他的业务包括诉讼和税法。Koski先生还担任Koski家族有限合伙公司的合伙人，该公司实益拥有该公司的权益，并自1996年12月起担任Koski家族基金会的董事。Koski先生拥有科尔盖特大学哲学和英语学士学位、埃默里法学院JD学位以及埃默里大学税务和诉讼法学硕士学位。
- Robert C. Koski,has served as a Director since June 2009. Mr. Koski has practiced as an attorney with the Koski Firm, a sole proprietorship located in Atlanta, Georgia since 1992, where his practice includes litigation and tax law. Mr. Koski has also served as a partner in the Koski Family Limited Partnership, which beneficially owns an interest in the Company, and as a Director of the Koski Family Foundation since December 1996. Mr. Koski holds a B.A. degree in Philosophy and English from Colgate University, a JD from Emory School of Law and an LLM degree in Taxation and Litigation from Emory University.
高管简历
中英对照 | 中文 | 英文- Kimberly M. Murphy
Kimberly M.Murphy自2020年5月起担任董事。加入公司之前，Murphy女士曾担任GlaxoSmithKline plc NYSE:GSK（“；GSK”；）流感专营权副总裁和全球疫苗商业化负责人，在那里她领导全球流感疫苗业务，全球疫苗和抗病毒药物的大流行准备，生命周期管理，业务开发和全球P&L管理。Murphy女士目前担任Blue Water AcquisitionCorp.（NASDAQ:BLUW）的董事。Murphy女士还担任Shingrix的带状疱疹疫苗的副总裁兼全球营销主管。从2014年6月到2015年5月，Murphy女士担任北美疫苗整合规划团队的副总裁和领导，负责GSK’；S收购Novartis AG’；S疫苗部门的整合规划。从2012年10月到2014年6月，她担任美国疫苗客户战略的副总裁，从2011年3月到2012年10月，她担任美国流感投资组合战略的高级总监。在2011年3月加入GSK之前，Murphy女士在Novartis Vaccines and Diagnostics Inc.（Novartis AG（NYSE:NVS）的一个部门）工作，担任美国脑膜炎球菌专营权的主管。在Novartis工作之前，Murphy女士在默克制药公司（NYSE:MRK）享有卓越的职业生涯。Murphy女士此前曾担任一家私营疫苗开发公司、生物技术行业组织、生物防御咨询委员会和圣约瑟夫大学制药和医疗保健营销MBA项目的董事会和顾问职务。Murphy女士拥有Old Dominion University的英语学士学位和Saint Joseph’；S University的市场营销硕士学位。墨菲还完成了宾夕法尼亚大学沃顿商学院（Wharton School of Pennsylvania）的卓越营销项目。
Kimberly M. Murphy was appointed President and Chief Executive Officer of the Company on June 23, 2022. She has served as a director since May 2020. Before joining the Company, Ms. Murphy served as Vice President of the Influenza Franchise and Global Vaccine Commercialization Leader at GlaxoSmithKline plc (NYSE: GSK) ("GSK"), where she led the global influenza vaccines business, global pandemic preparedness across vaccines and antivirals, lifecycle management, business development, and global P&L management. Ms. Murphy currently serves as a director of Blue Water Vaccines, Inc. (NASDAQ: BWV) and as a director (chairperson) of Clarus Therapeutics Holdings Inc. (OTC PK: CRXTQ). Ms. Murphy also served as Vice President and Global Marketing Head for the shingles vaccine, SHINGRIX. From June 2014 to May 2015, Ms. Murphy was Vice President and Lead for the North America Vaccines Integration Planning Team, responsible for the integration planning of GSK's acquisition of Novartis AG's vaccine division. From October 2012 to June 2014, Ms. Murphy served as Vice President of U.S. Vaccines Customer Strategy and from March 2011 to October 2012, she served as the Senior Director of U.S. Influenza Portfolio Strategy. Prior to joining GSK in March 2011, Ms. Murphy worked for Novartis Vaccines and Diagnostics Inc., a division of Novartis AG (NYSE: NVS), as the head of the U.S. Meningococcal Franchise. Before working for Novartis, Ms. Murphy enjoyed a distinguished career at Merck & Co., Inc. (NYSE: MRK). Ms. Murphy has previously served in board and advisory roles for a privately-held vaccine development company, the Biotechnology Industry Organization, the Biodefense Advisory Council, and the Saint Joseph's University Pharmaceutical & Healthcare Marketing MBA Program. Ms. Murphy holds a B.A. degree in English from Old Dominion University and a M.B.A. degree in Marketing from Saint Joseph's University. Ms. Murphy has also completed the Marketing Excellence Program at the Wharton School of the University of Pennsylvania.- Kimberly M.Murphy自2020年5月起担任董事。加入公司之前，Murphy女士曾担任GlaxoSmithKline plc NYSE:GSK（“；GSK”；）流感专营权副总裁和全球疫苗商业化负责人，在那里她领导全球流感疫苗业务，全球疫苗和抗病毒药物的大流行准备，生命周期管理，业务开发和全球P&L管理。Murphy女士目前担任Blue Water AcquisitionCorp.（NASDAQ:BLUW）的董事。Murphy女士还担任Shingrix的带状疱疹疫苗的副总裁兼全球营销主管。从2014年6月到2015年5月，Murphy女士担任北美疫苗整合规划团队的副总裁和领导，负责GSK’；S收购Novartis AG’；S疫苗部门的整合规划。从2012年10月到2014年6月，她担任美国疫苗客户战略的副总裁，从2011年3月到2012年10月，她担任美国流感投资组合战略的高级总监。在2011年3月加入GSK之前，Murphy女士在Novartis Vaccines and Diagnostics Inc.（Novartis AG（NYSE:NVS）的一个部门）工作，担任美国脑膜炎球菌专营权的主管。在Novartis工作之前，Murphy女士在默克制药公司（NYSE:MRK）享有卓越的职业生涯。Murphy女士此前曾担任一家私营疫苗开发公司、生物技术行业组织、生物防御咨询委员会和圣约瑟夫大学制药和医疗保健营销MBA项目的董事会和顾问职务。Murphy女士拥有Old Dominion University的英语学士学位和Saint Joseph’；S University的市场营销硕士学位。墨菲还完成了宾夕法尼亚大学沃顿商学院（Wharton School of Pennsylvania）的卓越营销项目。
- Kimberly M. Murphy was appointed President and Chief Executive Officer of the Company on June 23, 2022. She has served as a director since May 2020. Before joining the Company, Ms. Murphy served as Vice President of the Influenza Franchise and Global Vaccine Commercialization Leader at GlaxoSmithKline plc (NYSE: GSK) ("GSK"), where she led the global influenza vaccines business, global pandemic preparedness across vaccines and antivirals, lifecycle management, business development, and global P&L management. Ms. Murphy currently serves as a director of Blue Water Vaccines, Inc. (NASDAQ: BWV) and as a director (chairperson) of Clarus Therapeutics Holdings Inc. (OTC PK: CRXTQ). Ms. Murphy also served as Vice President and Global Marketing Head for the shingles vaccine, SHINGRIX. From June 2014 to May 2015, Ms. Murphy was Vice President and Lead for the North America Vaccines Integration Planning Team, responsible for the integration planning of GSK's acquisition of Novartis AG's vaccine division. From October 2012 to June 2014, Ms. Murphy served as Vice President of U.S. Vaccines Customer Strategy and from March 2011 to October 2012, she served as the Senior Director of U.S. Influenza Portfolio Strategy. Prior to joining GSK in March 2011, Ms. Murphy worked for Novartis Vaccines and Diagnostics Inc., a division of Novartis AG (NYSE: NVS), as the head of the U.S. Meningococcal Franchise. Before working for Novartis, Ms. Murphy enjoyed a distinguished career at Merck & Co., Inc. (NYSE: MRK). Ms. Murphy has previously served in board and advisory roles for a privately-held vaccine development company, the Biotechnology Industry Organization, the Biodefense Advisory Council, and the Saint Joseph's University Pharmaceutical & Healthcare Marketing MBA Program. Ms. Murphy holds a B.A. degree in English from Old Dominion University and a M.B.A. degree in Marketing from Saint Joseph's University. Ms. Murphy has also completed the Marketing Excellence Program at the Wharton School of the University of Pennsylvania.
- Janet Huffman
Janet Huffman，于2022年2月加入公司，担任财务总监。2022年3月31日，董事会批准任命Huffman女士为公司首席财务官兼首席财务/会计官，自Howard A Doss辞职生效后，自2022年4月2日起生效。霍夫曼女士曾在医疗保健行业担任过多个财务职务。2009年，霍夫曼女士加入Infinity Home Care，担任财务总监和区域运营总监，直至2013年。从2013年到2014年，霍夫曼女士担任Internal Medicine Associates的财务总监，从2014年到2016年，她担任Family Home Health Services的财务副总裁。从2017年2月开始，一直到2020年1月，霍夫曼女士担任总部位于肯塔基州的医疗保健公司Signature Home Now的首席财务官。霍夫曼女士担任首席财务官期间，她支持家庭健康部门提供财务和运营指导。2019年1月，霍夫曼成为Banyan Pediatric Care Centers，Inc的创始人之一，担任该公司的首席财务官；2021年，霍夫曼带领Banyan与Arboreta Healthcare Inc.合并，继续担任该公司的首席财务官，直至2022年2月。她获得了南佛罗里达大学会计学学士学位。
Janet Huffman,has served as Oragenics, Inc. Chief Financial Officer since March 8, 2023. On January 21, 2025, Ms. Huffman was also appointed as Interim Chief Executive Officer. Most recently, Ms. Huffman served as Chief Financial Officer for TRxADE HEALTH, Inc., a Nasdaq-listed company focused on health services IT for retail pharmacies. In 2019, Ms. Huffman was a founding member of Banyan Pediatric Care Centers and served as its Chief Financial Officer. After leading Banyan's merger with Assisted 4 Living, Inc., an OTC-listed company later renamed Arboreta Healthcare Inc. and a provider of skilled nursing, rehabilitation and assisted living services, she continued as Chief Financial Officer until February 2022. Prior to Arboreta Healthcare, Ms. Huffman was the Chief Financial Officer for Signature HomeNow, a home healthcare services company. Earlier in her career, she served as Director of Finance and Regional Director of Operations for Infinity Homecare and was Vice President of Finance for Family Home Health Services. Ms. Huffman obtained a B.S.in accounting from the University of South Florida.- Janet Huffman，于2022年2月加入公司，担任财务总监。2022年3月31日，董事会批准任命Huffman女士为公司首席财务官兼首席财务/会计官，自Howard A Doss辞职生效后，自2022年4月2日起生效。霍夫曼女士曾在医疗保健行业担任过多个财务职务。2009年，霍夫曼女士加入Infinity Home Care，担任财务总监和区域运营总监，直至2013年。从2013年到2014年，霍夫曼女士担任Internal Medicine Associates的财务总监，从2014年到2016年，她担任Family Home Health Services的财务副总裁。从2017年2月开始，一直到2020年1月，霍夫曼女士担任总部位于肯塔基州的医疗保健公司Signature Home Now的首席财务官。霍夫曼女士担任首席财务官期间，她支持家庭健康部门提供财务和运营指导。2019年1月，霍夫曼成为Banyan Pediatric Care Centers，Inc的创始人之一，担任该公司的首席财务官；2021年，霍夫曼带领Banyan与Arboreta Healthcare Inc.合并，继续担任该公司的首席财务官，直至2022年2月。她获得了南佛罗里达大学会计学学士学位。
- Janet Huffman,has served as Oragenics, Inc. Chief Financial Officer since March 8, 2023. On January 21, 2025, Ms. Huffman was also appointed as Interim Chief Executive Officer. Most recently, Ms. Huffman served as Chief Financial Officer for TRxADE HEALTH, Inc., a Nasdaq-listed company focused on health services IT for retail pharmacies. In 2019, Ms. Huffman was a founding member of Banyan Pediatric Care Centers and served as its Chief Financial Officer. After leading Banyan's merger with Assisted 4 Living, Inc., an OTC-listed company later renamed Arboreta Healthcare Inc. and a provider of skilled nursing, rehabilitation and assisted living services, she continued as Chief Financial Officer until February 2022. Prior to Arboreta Healthcare, Ms. Huffman was the Chief Financial Officer for Signature HomeNow, a home healthcare services company. Earlier in her career, she served as Director of Finance and Regional Director of Operations for Infinity Homecare and was Vice President of Finance for Family Home Health Services. Ms. Huffman obtained a B.S.in accounting from the University of South Florida.
- Joseph Michael Redmond
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介
- Charles L. Pope
Charles L. Pope，自2008年9月以来一直是本董事会的成员。他曾在2009年6月以来一直在Florida州Tampa市的一个社区银行- The Palm Bank的首席运营官及财务总监。在2007-2009年期间，他曾在一家飞机仪器和显示器的制造商- Aerosonic公司的财务总监及顾问。在2005年2月-2007年4月期间，他曾在一个电子服务和工程服务的生产商- Reptron Manufacturing的财务总监。在2002年4月-2005年2月期间，他曾是一家为医院手术过程中可重复使用和一次性产品的供应商- SRI/Surgical的一位财务总监。此前，他曾在一个收购和投资高校新技术开发的商业开发公司- UTEK公司的财务总监。在2010年2月以来，他一直是Innovaro股份有限公司（OTCQB： INNI）的董事会成员，以及是审计委员会的主席。自2010年6月以来，他一直是Oragenics股份有限公司 （OTCBB： OGEN）的董事会成员，以及是其审计委员会的主席。他曾经在PricewaterhouseCoopers律师事务所工作，最后作为合伙人的身份离开。他拥有Auburn大学的经济和会计学士学位，以及是Florida州的一名注册会计师。
Charles L. Pope,was elected Chairman on December 16, 2022, and has served as a Director since June 2010. Mr. Pope served as the Chief Financial Officer of Palm Bancorp, Inc. from June 2009 to June 2012. From September 2007 through June 2009, Mr. Pope served as the Chief Financial Officer of Aerosonic Inc., a manufacturer of aviation products. Mr. Pope served as the Chief Financial Officer of Reptron Inc., a manufacturer of electronic products, from March 2005 through June 2007. From March 2002 to March 2005, Mr. Pope served as Chief Financial Officer of SRI/Surgical Express, Inc. From February 2001 to March 2002, Mr. Pope served as Chief Financial Officer of Innovaro, Inc. (formerly UTEK Corporation NYSE American: INV) a public company. Mr. Pope served as a Director for Trxade Health, Inc. (NASDAQ: MEDS). Mr. Pope served as a Director of Innovaro, Inc. from March 2010 to August 2012. Mr. Pope also served as a director of Inuvo, Inc. from July 2008 through July 2018. Prior to this time, Mr. Pope served as a Partner in the Audit and Financial Advisory Consulting Divisions of PricewaterhouseCoopers LLP, and he was also a Partner in the Accounting and SEC Directorate in PricewaterhouseCoopers LLP's New York City office. Mr. Pope holds a B.S. degree in Economics and Accounting from Auburn University and is a Certified Public Accountant in Florida.- Charles L. Pope，自2008年9月以来一直是本董事会的成员。他曾在2009年6月以来一直在Florida州Tampa市的一个社区银行- The Palm Bank的首席运营官及财务总监。在2007-2009年期间，他曾在一家飞机仪器和显示器的制造商- Aerosonic公司的财务总监及顾问。在2005年2月-2007年4月期间，他曾在一个电子服务和工程服务的生产商- Reptron Manufacturing的财务总监。在2002年4月-2005年2月期间，他曾是一家为医院手术过程中可重复使用和一次性产品的供应商- SRI/Surgical的一位财务总监。此前，他曾在一个收购和投资高校新技术开发的商业开发公司- UTEK公司的财务总监。在2010年2月以来，他一直是Innovaro股份有限公司（OTCQB： INNI）的董事会成员，以及是审计委员会的主席。自2010年6月以来，他一直是Oragenics股份有限公司 （OTCBB： OGEN）的董事会成员，以及是其审计委员会的主席。他曾经在PricewaterhouseCoopers律师事务所工作，最后作为合伙人的身份离开。他拥有Auburn大学的经济和会计学士学位，以及是Florida州的一名注册会计师。
- Charles L. Pope,was elected Chairman on December 16, 2022, and has served as a Director since June 2010. Mr. Pope served as the Chief Financial Officer of Palm Bancorp, Inc. from June 2009 to June 2012. From September 2007 through June 2009, Mr. Pope served as the Chief Financial Officer of Aerosonic Inc., a manufacturer of aviation products. Mr. Pope served as the Chief Financial Officer of Reptron Inc., a manufacturer of electronic products, from March 2005 through June 2007. From March 2002 to March 2005, Mr. Pope served as Chief Financial Officer of SRI/Surgical Express, Inc. From February 2001 to March 2002, Mr. Pope served as Chief Financial Officer of Innovaro, Inc. (formerly UTEK Corporation NYSE American: INV) a public company. Mr. Pope served as a Director for Trxade Health, Inc. (NASDAQ: MEDS). Mr. Pope served as a Director of Innovaro, Inc. from March 2010 to August 2012. Mr. Pope also served as a director of Inuvo, Inc. from July 2008 through July 2018. Prior to this time, Mr. Pope served as a Partner in the Audit and Financial Advisory Consulting Divisions of PricewaterhouseCoopers LLP, and he was also a Partner in the Accounting and SEC Directorate in PricewaterhouseCoopers LLP's New York City office. Mr. Pope holds a B.S. degree in Economics and Accounting from Auburn University and is a Certified Public Accountant in Florida.